Wang et al. used HER2/neu-specific Neu-T cell derived exosome (TEXO) and HER2-TEXO vaccines by transfecting DCs to stimulate HER2/neu-specific CTLs and study anti-tumor activity. The gene discussed is ERBB2; the disease is neoplasm.